• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet stock rises on Street-beating Q4, expected Omnipod growth

February 24, 2023 By Sean Whooley

Insulet logoInsulet (Nasdaq:PODD) shares ticked up today — a day after releasing fourth-quarter results that came in well ahead of the consensus forecast.

Shares of PODD were up slightly to $299.29 apiece by midday trading today.

The Acton, Massachusetts-based automated insulin technology developer posted profits of $17 million. That amounts to 24¢ per share on sales of $369.7 million for the three months ended Dec. 31, 2022.

Insulet recorded a 41.8% bottom-line slide despite sales growth of 20.1%. Its global Omnipod revenues — including the latest-generation Omnipod 5 — totaled $366.4 million for the quarter. That marks 32.8% year-over-year growth. Omnipod growth for the full year came in at 23.4%, reaching $1.2 billion in sales.

Adjusted to exclude one-time items, earnings per share totaled $1.28. That landed well ahead of expectations on Wall Street, topping estimates by $1.07. Insulet posted a sales beat, too, handily beating analysts’ projections of $330.4 million.

“2022 was another successful year for Insulet as we delivered strong revenue growth and advanced our strategic priorities,” said Jim Hollingshead, Insulet president and CEO. “We entered 2023 with significant momentum and expect to further strengthen our foundation for long-term sustainable growth. We are excited about the commercial launch of Omnipod 5, which is a transformative technology offering users award-winning innovation and improved outcomes and quality of life.

“We are proud of all we have accomplished and the entire Insulet team is focused on building on our success and furthering our mission to improve the lives of people with diabetes.”

Insulet expects to post revenue growth between 14% and 19% in 2023. It projects 17%-22% growth for total Omnipod sales.

Analyst’s view

BTIG’s Marie Thibault continues to list a “Buy” rating for Insulet. In a report, she wrote that encouragement comes from new growth drivers shared by Insulet. Those could include iOS integration, type 2 diabetes expansion, adoption tailwinds from next-generation CGMs and an international launch.

“We continue to be impressed by the [Omnipod 5] market introduction,” Thibault wrote. “With robust patient volume growth and strong ordering patterns, our U.S. Omnipod revenue projection moves higher.”

This story originally ran on Feb. 23, 2023. Updated Feb. 24 with the next-day stock price. 

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Insulet

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS